About

OTCQB:MRLA

Early Detection of Skin Cancer

About DermaCompare

DermaCompare (OTCQB:MRLA) is a revolutionary skin cancer screening platform that enables physicians to identify and monitor changes in their patients’ skin characteristics. DermaCompare was developed by Emerald Medical Applications, a digital health startup. Emerald specializes in image processing software infrastructure solutions for an extensive range of applications for diverse medical unmet needs. Emerald’s technology utilizes the knowledge of military image processing and big data analytics to improve the analysis of medical images for the benefit of patients and the medical community alike.

DermaCompare is the first application of Emerald’s technology and innovation and it is set to revolutionize the world of dermatology and aid the early detection of skin cancer.

MANAGEMENT TEAM

lior-wayn

Lior Wayn

Founder

Lior Wayn founded Emerald Medical Applications based on a family experience of a failed diagnosis of melanoma. In this he has harnessed his vast experience in the information and communications technologies (ICT) industry and his know how in mobilizing teams for large and complex projects. Before forming Emerald, Lior had worked in sales and business development of some of Israel’s leading ICT organizations like Ness Technologies, EIM and Malam Team. Lior holds a BA in business administration from the Ruppin Academic Center.

Alon

Dr Alon Scope

Medical Advisor

Dr. Scope is a board-certified dermatologist, director of the melanoma and pigmented lesion clinic at Sheba Medical Center and a research tract senior lecturer at Tel Aviv University. After graduating from his MD studies (Magna Cum Laude) at Tel Aviv University and dermatology residency (Honors) at Sheba Medical Center, Dr. Scope completed a Dermato-oncology fellowship at Memorial Sloan Kettering Cancer Center in New York and a Dermato-pathology fellowship at the Ackerman Academy in New York. He is an internationally recognized expert in dermoscopy and confocal microscopy. He has co-authored over 120 publications in peer-reviewed journals and 27 scientific book chapters, with a major focus on diagnosis and non-invasive imaging of melanoma and nevi. In recognition of his research achievements, Dr. Scope received in 2009 the prestigious “Paolo Carli Award” for Scientific Excellence and World-Leading Contributions to Dermoscopic Research between the years 2006-2009, granted at the 2nd World Congress of Dermoscopy. Dr. Scope gave in 2012 the keynote lecture on nevogenesis at the 3rd World Congress of Dermoscopy in Brisbane, Australia and in 2015 a plenary lecture on diagnosis of nevi in children at the 4th World Congress of Dermoscopy in Vienna. In 2016, he received the “Friedberg Fund Award” for Research in Medicine granted by the Israel Science Foundation.